Japanese Drug Wholesalers Call Off Planned Merger Citing Regulatory Hurdles
This article was originally published in PharmAsia News
Executive Summary
Japan's biggest drug wholesaler Mediceo Paltac called off a plan to buy rival Alfresa Holdings, citing a delay in approval by regulators. At a Jan. 9 press briefing, Mediceo Executive Director Genichiro Tanabe commented that both companies realized that it would take longer than the previously planned April 1 date for the Fair Trade Commission to clear the deal. The delay will result in high risks of loss of profits and unrealized synergy effects. However, both Tanabe and Alfresa board director Shozo Hasebe did not rule out the possibility of a merger in future. Mediceo Platac launched a ¥203 billion bid for Alfresa. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.